Ad Code: Ingrezza - Display Banners Condition Spotlight - Oct - ING Pref - 155682

As this year is nearing the end, PW recaps some of the research presented tardive dyskinesia in 2024. 

Transcranial direct current stimulation shows potential as an effective, safe treatment for improving the facial-oral motor symptoms of tardive dyskinesia.

While uncommon, vocal cord dysfunction related to tardive dyskinesia can occur and may be life-threatening.

Patients and physicians agreed that tardive dyskinesia caused significant work impairment, with some patients completely unable to obtain or maintain a job.

Recent research published in 2024 examined various tardive dyskinesia topics, including: transcranial direct current stimulation; new clinical tool for documenting and rating TD; and schizophrenia-associated genetic markers.

Researchers analyzed whether valbenazine’s impact on tardive dyskinesia symptoms varied between patients with schizophrenia versus bipolar disorder.

Authors of a recent review outlined barriers to tardive dyskinesia diagnosis and how neurologists and psychiatrists can collaborate to optimize care.

Dr. Eiry Roberts discusses why clinicians should avoid anticholinergics in patients with tardive...

Several clinical trials have tested the efficacy and safety of valbenazine and deutetrabenazine in patients with TD.

Deep brain stimulation offers advantages such as adjustability, reversibility, and the potential for rapid and long-term improvement in tardive dyskinesia.

Annual training and reliable new tools can help physicians improve tardive dyskinesia screening and symptom measurement.

There are approximately 600,000 people in the US who are living with TD—65% of them have not been diagnosed.

The Tardive Dyskinesia Impact Scale complements the Abnormal Involuntary Movement Scale by combining clinician-rated and patient-reported perspectives.

The Extrapyramidal Symptom Rating Scale and an abbreviated version of the scale were both validated for measuring the impact of tardive dyskinesia.